Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Apellis Pharmaceuticals, Inc.    APLS

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
02/26/2020 | 07:01am EDT

WALTHAM, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the 40th Annual Cowen Health Care Conference on Wednesday, March 4, 2020 at 10:00 a.m. ET in Boston, Mass.

The presentation will be given by Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, and will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at http://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.

Investor Contact:
Sam Martin / Maghan Meyers
Argot Partners
sam@argotpartners.com / maghan@argotpartners.com
212.600.1902

Media Contact:
Tracy Vineis
media@apellis.com
617.420.4839

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on APELLIS PHARMACEUTICALS, I
03/04APELLIS PHARMACEUTICALS : March Corporate Presentation
PU
02/27APELLIS PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2019 Financial Re..
AQ
02/27APELLIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
02/26Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Confe..
GL
01/16Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule..
GL
01/13APELLIS PHARMACEUTICALS : Announces Closing of Public Offering of Common Stock a..
AQ
01/09Blackstone raises three-quarters of targeted $4.6 billion life sciences fund
RE
01/09APELLIS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Othe..
AQ
01/08Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GL
01/08APELLIS PHARMACEUTICALS : Reports Positive Top-line Results from Phase 3 Head-to..
AQ
More news
Financials (USD)
Sales 2020 -
EBIT 2020 -423 M
Net income 2020 -433 M
Finance 2020 118 M
Yield 2020 -
P/E ratio 2020 -4,59x
P/E ratio 2021 -4,66x
EV / Sales2020 infx
EV / Sales2021 79,8x
Capitalization 1 968 M
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 52,82  $
Last Close Price 26,13  $
Spread / Highest target 229%
Spread / Average Target 102%
Spread / Lowest Target 11,0%
EPS Revisions
Managers
NameTitle
Cedric Francois President, Chief Executive Officer & Director
Lok Chung Chan Chairman
Pascal Deschatelets Chief Operating Officer
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Federico Grossi Senior VP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
APELLIS PHARMACEUTICALS, INC.-17.54%2 018
CSL LIMITED0.00%82 637
BIOGEN INC.1.27%55 070
SAMSUNG BIOLOGICS CO.,LTD.5.93%26 232
ALEXION PHARMACEUTICALS-16.46%19 942
GRIFOLS0.00%19 665